BR112012028462A2 - liberação de éster de colesterol para tecidos esteroidogênicos - Google Patents

liberação de éster de colesterol para tecidos esteroidogênicos

Info

Publication number
BR112012028462A2
BR112012028462A2 BR112012028462A BR112012028462A BR112012028462A2 BR 112012028462 A2 BR112012028462 A2 BR 112012028462A2 BR 112012028462 A BR112012028462 A BR 112012028462A BR 112012028462 A BR112012028462 A BR 112012028462A BR 112012028462 A2 BR112012028462 A2 BR 112012028462A2
Authority
BR
Brazil
Prior art keywords
tissues
cholesterol ester
steroid
release
ester release
Prior art date
Application number
BR112012028462A
Other languages
English (en)
Inventor
Brian KRAUSE
Bruce J Auerbach
Reynold Homan
Original Assignee
Alphacore Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphacore Pharma Llc filed Critical Alphacore Pharma Llc
Publication of BR112012028462A2 publication Critical patent/BR112012028462A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

liberação de éster de colesterol para tecidos esteroidogênicos. a presente invenção refere-se a composições e métodos para tratar condições caracterizadas por hdl-ce baixo, o que pode levar à redução da liberação de éster de colesterol para os tecidos esteroidogênicos, reduzindo a capacidade do órgão de produzir esteroides, especialmente durante os períodos de demanda, estresse e/ou síndrome de resposta inflamatória sistêmica.
BR112012028462A 2010-05-06 2011-05-06 liberação de éster de colesterol para tecidos esteroidogênicos BR112012028462A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190910P 2010-05-06 2010-05-06
PCT/US2011/035500 WO2011140429A1 (en) 2010-05-06 2011-05-06 Delivery of cholesteryl ester to steroidogenic tissues

Publications (1)

Publication Number Publication Date
BR112012028462A2 true BR112012028462A2 (pt) 2016-07-19

Family

ID=44121177

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012028462A BR112012028462A2 (pt) 2010-05-06 2011-05-06 liberação de éster de colesterol para tecidos esteroidogênicos

Country Status (22)

Country Link
US (2) US20130045194A1 (pt)
EP (1) EP2566505B1 (pt)
JP (1) JP6174995B2 (pt)
CN (1) CN103025348B (pt)
AU (1) AU2011247985B2 (pt)
BR (1) BR112012028462A2 (pt)
CA (1) CA2797126C (pt)
CY (1) CY1122827T1 (pt)
DK (1) DK2566505T3 (pt)
ES (1) ES2764733T3 (pt)
HR (1) HRP20200008T1 (pt)
HU (1) HUE047288T2 (pt)
LT (1) LT2566505T (pt)
ME (1) ME03682B (pt)
MX (1) MX336872B (pt)
NZ (1) NZ603453A (pt)
PL (1) PL2566505T3 (pt)
PT (1) PT2566505T (pt)
RS (1) RS59867B1 (pt)
RU (1) RU2012152320A (pt)
SI (1) SI2566505T1 (pt)
WO (1) WO2011140429A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2853259A1 (en) * 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
CN111601614A (zh) * 2017-11-07 2020-08-28 阿尔法科制药有限责任公司 治疗和预防心脏病、心血管疾病及相关病症和症状的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0910343A1 (en) * 1996-07-03 1999-04-28 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
CA2284832A1 (en) * 1997-04-11 1998-10-22 Takeda Chemical Industries, Ltd. Proteins having lecithin-cholesterol acyltransferase-like activity, their production and use
US7758893B2 (en) * 2001-07-27 2010-07-20 N.V. Nutricia Enteral compositions for the prevention and/or treatment of sepsis
IL158554A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Mimetic lipids as dietary supplements
US20070208003A1 (en) 2004-03-26 2007-09-06 Bell Michael G Compounds and methods for treating dyslipidemia
US20080096900A1 (en) 2006-06-26 2008-04-24 Amgen Inc. Methods for treating atherosclerosis
ES2449483T3 (es) * 2007-07-26 2014-03-19 Amgen, Inc Enzimas lecitina-colesterol aciltransferasa modificadas
WO2009124055A1 (en) * 2008-03-31 2009-10-08 University Of Chicago Human apoa-i mutants
CA2764189C (en) * 2009-06-12 2019-04-30 Alphacore Pharma Llc Use of lcat for treating anemia and red blood cell dysfunction

Also Published As

Publication number Publication date
AU2011247985B2 (en) 2015-12-03
HRP20200008T1 (hr) 2020-03-20
AU2011247985A1 (en) 2012-11-29
US20150190479A1 (en) 2015-07-09
CA2797126A1 (en) 2011-11-10
EP2566505A1 (en) 2013-03-13
ES2764733T3 (es) 2020-06-04
JP2013528594A (ja) 2013-07-11
MX336872B (es) 2016-02-04
PL2566505T3 (pl) 2020-06-29
CN103025348A (zh) 2013-04-03
DK2566505T3 (da) 2020-01-20
JP6174995B2 (ja) 2017-08-02
MX2012012711A (es) 2012-11-21
NZ603453A (en) 2014-12-24
CA2797126C (en) 2020-06-02
LT2566505T (lt) 2020-02-10
ME03682B (me) 2021-01-20
RU2012152320A (ru) 2014-06-20
WO2011140429A1 (en) 2011-11-10
SI2566505T1 (sl) 2020-03-31
HUE047288T2 (hu) 2020-04-28
CY1122827T1 (el) 2021-05-05
PT2566505T (pt) 2020-01-15
EP2566505B1 (en) 2019-10-16
US20130045194A1 (en) 2013-02-21
RS59867B1 (sr) 2020-03-31
CN103025348B (zh) 2015-09-02

Similar Documents

Publication Publication Date Title
ECSP17057848A (es) Composiciones farmacéuticas para terapia combinada
UA108637C2 (uk) Пінна композиція, що містить щонайменше один тритерпеноїд та одну мембраноутворюючу сполуку
BR112012010083B8 (pt) Composição farmacêutica tópica de liberação sustentada e uso relacionado
PH12013501319A1 (en) Fatty acid acetylated salicylates and their uses
SG178948A1 (en) Fatty acid niacin conjugates and their uses
BRPI0715073A8 (pt) métodos e composições para inibir a angiogênese
CL2017003288A1 (es) Métodos para tratar o prevenir enfermedades relacionadas con el colesterol (divisional solicitud 201303214)
MX2022013429A (es) Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico.
BR112013017635A2 (pt) inibidores de cyp11b, cyp17 e/ou cyp21
BRPI0800991A2 (pt) composiÇÕes para uso no escurecimento da pele
BR112013031389A2 (pt) instrumento cirúrgico
MX2010002592A (es) Composicion farmaceutica topica para la combinacion de acido fusidico y corticoesteroides.
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
EP3354640A3 (en) Mif inhibitors and their uses
BR112014014410A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
BR112013000776A2 (pt) método e formulação para tratamento de deficiência de ácido siálico
BR112013003216A2 (pt) composições sintéticas de ácido biliar e métodos
BR112014009376A2 (pt) composições
WO2008012338A3 (en) Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
BR112014032759A2 (pt) composições lipídicas de racecadotril
WO2013049599A3 (en) Personal compositions with silicone emulsifier-free natural emulsifier system
BR112013026241A2 (pt) sistema e método para liberação multifásica de fatores de crescimento
BR112012029697A2 (pt) polissacarídeo da semente de tamarindo para uso no tratamento de doenças inflamatórias
WO2013007637A3 (en) Cosmetic compositions in the form of water-in-oil emulsions including a jasmonic acid derivative and a silicone surfactant
BR112015030343A2 (pt) composições e métodos para redução ou prevenção de metástase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]